Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin.
In twelve patients affected by small bowel bacterial overgrowth, diagnosed by means of the lactulose hydrogen breath test, the therapeutic efficacy of a non-absorbable derivative of rifamycin, rifaximin, was evaluated. This study showed that this drug has a satisfactory therapeutic efficacy in contaminated small bowel syndrome and, at the doses tested, is free of side-effects.
Corazza
G R
GR
Department of Medical Pathology, University of Bologna, Italy.
Ventrucci
M
M
Strocchi
A
A
Sorge
M
M
Pranzo
L
L
Pezzilli
R
R
Gasbarrini
G
G
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D001944:Breath Tests; D002648:Child; D005260:Female; D006801:Humans; D007410:Intestinal Diseases / Q000188:drug therapy* / Q000382:microbiology; D007421:Intestine, Small / Q000382:microbiology*; D007792:Lactulose; D008297:Male; D008875:Middle Aged; D012294:Rifamycins / Q000627:therapeutic use*; D000078262:Rifaximin
D012294:Rifamycins; D007792:Lactulose; D000078262:Rifaximin